|
1
|
Chang HK, Gen Y, Yeo SG, Jung JH and Park
DC: Primary adenocarcinoma with choriocarcinomatous differentiation
of the sigmoid colon misdiagnosed choriocarcinoma of the uterus:
Case report and review of the literature. Eur J Gynaecol Oncol.
40:468–470. 2019.
|
|
2
|
Lian J, Xia L, Chen Y, Zheng J, Ma K, Luo
L and Ye F: Aldolase B impairs DNA mismatch repair and induces
apoptosis in colon adenocarcinoma. Pathol Res Pract.
215(152597)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kai K, Hidaka H, Nakamura T, Ueda Y,
Marutsuka K, Ikeda T and Nanashima A: A case of poorly
differentiated adenocarcinoma with lymphoid stroma originated in
the ascending colon diagnosed as lymphoepithelioma-like carcinoma.
Clin J Gastroenterol. 13:538–544. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Li Z, Tan H, Yu H, Deng Z, Zhou X and Wang
M: DNA methylation and gene expression profiles characterize
epigenetic regulation of lncRNAs in colon adenocarcinoma. J Cell
Biochem. 121:2406–2415. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bottino C, Peserico A, Simone C and
Caretti G: SMYD3: An oncogenic driver targeting epigenetic
regulation and signaling pathways. Cancers (Basel).
12(142)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Dong S and Zhang P: Advances of histone
methyltransferase SMYD3 in tumors. Zhongguo Fei Ai Za Zhi.
17:689–694. 2014.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
7
|
Eberle CA, Zayas M, Stukalov A, Pichlmair
A, Alvisi G, Muller AC, Bennett KL, Bartenschlager R and
Superti-Furga G: The lysine methyltransferase SMYD3 interacts with
hepatitis C virus NS5A and is a negative regulator of viral
particle production. Virology. 462-463:34–41. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chen YJ, Tsai CH, Wang PY and Teng SC:
SMYD3 promotes homologous recombination via regulation of
H3K4-mediated gene expression. Sci Rep. 7(3842)2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wang Q, Jiang Y, Luo X, Wang C, Wang N, He
H, Zhang T and Chen L: Chitooligosaccharides modulate glucose-lipid
metabolism by suppressing SMYD3 pathways and regulating gut
microflora. Mar Drugs. 18(69)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chen J, He Z, Yuan Y, Huang F, Luo B and
Zhang J, Pan T, Zhang H and Zhang J: Host factor SMYD3 is recruited
by Ebola virus nucleoprotein to facilitate viral mRNA
transcription. Emerg Microbes Infect. 8:1347–1360. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Al-Eitan LN and Rababa'h DM: Correlation
between a variable number tandem repeat (VNTR) polymorphism in
SMYD3 gene and breast cancer: A genotype-phenotype study. Gene.
728(144281)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chen D, Liu L, Luo X, Mu A, Yan L, Chen X,
Wang L, Wang N, He H, Zhou H and Zhang T: Effect of SMYD3 on the
microRNA expression profile of MCF-7 breast cancer cells. Oncol
Lett. 14:1831–1840. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cock-Rada AM, Medjkane S, Janski N, Yousfi
N, Perichon M, Chaussepied M, Chluba J, Langsley G and Weitzman JB:
SMYD3 promotes cancer invasion by epigenetic upregulation of the
metalloproteinase MMP-9. Cancer Res. 72:810–820. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Colon-Bolea P and Crespo P: Lysine
methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the
Ras-ERK pathway. Bioessays. 36:1162–1169. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Dong QQ, Wang QT, Wang L, Jiang YX, Liu
ML, Hu HJ, Liu Y, Zhou H, He HP, Zhang TC and Luo XG:
SMYD3-associated pathway is involved in the anti-tumor effects of
sulforaphane on gastric carcinoma cells. Food Sci Biotechnol.
27:1165–1173. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Fei X, Ma Y, Liu X and Meng Z:
Overexpression of SMYD3 is predictive of unfavorable prognosis in
hepatocellular carcinoma. Tohoku J Exp Med. 243:219–226.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fenizia C, Bottino C, Corbetta S,
Fittipaldi R, Floris P, Gaudenzi G, Carra S, Cotelli F, Vitale G
and Caretti G: SMYD3 promotes the epithelial-mesenchymal transition
in breast cancer. Nucleic Acids Res. 47:1278–1293. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jiang Y, Lyu T, Che X, Jia N, Li Q and
Feng W: Overexpression of SMYD3 in ovarian cancer is associated
with ovarian cancer proliferation and apoptosis via methylating
H3K4 and H4K20. J Cancer. 10:4072–4084. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Li B, Pan R, Zhou C, Dai J, Mao Y, Chen M,
Huang T, Ying X, Hu H, Zhao J, et al: SMYD3 promoter
hypomethylation is associated with the risk of colorectal cancer.
Future Oncol. 14:1825–1834. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Liu C, Wang C, Wang K, Liu L, Shen Q, Yan
K, Sun X, Chen J, Liu J, Ren H, et al: SMYD3 as an oncogenic driver
in prostate cancer by stimulation of androgen receptor
transcription. J Natl Cancer Inst. 105:1719–1728. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wang Y, Xie BH, Lin WH, Huang YH, Ni JY,
Hu J, Cui W, Zhou J, Shen L, Xu LF, et al: Amplification of SMYD3
promotes tumorigenicity and intrahepatic metastasis of
hepatocellular carcinoma via upregulation of CDK2 and MMP2.
Oncogene. 38:4948–4961. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Nowak A, Zaklos-Szyda M, Zyzelewicz D,
Koszucka A and Motyl I: Acrylamide decreases cell viability, and
provides oxidative stress, DNA damage, and apoptosis in human colon
adenocarcinoma cell line caco-2. Molecules. 25(368)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yang Y, Zhao Z, Xie C and Zhao Y:
Dual-targeting liposome modified by glutamic hexapeptide and folic
acid for bone metastatic breast cancer. Chem Phys Lipids.
228(104882)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhao Z, Zhao Y, Xie C, Chen C, Lin D, Wang
S, Lin D, Cui X, Guo Z and Zhou J: Dual-active targeting liposomes
drug delivery system for bone metastatic breast cancer: Synthesis
and biological evaluation. Chem Phys Lipids.
223(104785)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ruan GT, Zhu LC, Gong YZ, Liao XW, Wang
XK, Liao C, Wang S, Yan L, Xie HL, Zhou X, et al: The diagnosis and
prognosis values of WNT mRNA expression in colon adenocarcinoma. J
Cell Biochem. 121:3145–3161. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ni X, Ding Y, Yuan H, Shao J, Yan Y, Guo
R, Luan W and Xu M: Long non-coding RNA ZEB1-AS1 promotes colon
adenocarcinoma malignant progression via miR-455-3p/PAK2 axis. Cell
Prolif. 53(e12723)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chang CL, Yuan KS, Wu ATH and Wu SY:
Adjuvant therapy for high-risk stage II or III colon
adenocarcinoma: A propensity score-matched, nationwide,
population-based cohort study. Cancers (Basel).
11(2003)2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Chan KWK, Chung HY and Ho WS: Anti-tumor
activity of atractylenolide I in human colon adenocarcinoma in
vitro. Molecules. 25(212)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhang L, Jin Y, Yang H, Li Y, Wang C, Shi
Y and Wang Y: SMYD3 promotes epithelial ovarian cancer metastasis
by downregulating p53 protein stability and promoting p53
ubiquitination. Carcinogenesis. 40:1492–1503. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Liu N, Sun S and Yang X: Prognostic
significance of stromal SMYD3 expression in colorectal cancer of
TNM stage I-III. Int J Clin Exp Pathol. 10:8901–8907.
2017.PubMed/NCBI
|
|
32
|
Liu TT, Xu H, Gao WP, Zhang SX, Zhou XH,
Tang J and Liu QN: SET and MYND domain-containing protein 3 (SMYD3)
polymorphism as a risk factor for susceptibility and poor prognosis
in ovarian cancer. Med Sci Monit. 22:5131–5140. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lyu T, Jiang Y, Jia N, Che X, Li Q, Yu Y,
Hua K, Bast RC Jr and Feng W: SMYD3 promotes implant metastasis of
ovarian cancer via H3K4 trimethylation of integrin promoters. Int J
Cancer. 146:1553–1567. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhu CL and Huang Q: Overexpression of the
SMYD3 promotes proliferation, migration, and invasion of pancreatic
cancer. Dig Dis Sci. 65:489–499. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Bai H, Li Y, Gao H, Dong Y, Han P and Yu
H: Histone methyltransferase SMYD3 regulates the expression of
transcriptional factors during bovine oocyte maturation and early
embryonic development. Cytotechnology. 68:849–859. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Sun J, Shi F and Yang N: Exploration of
the substrate preference of lysine methyltransferase SMYD3 by
molecular dynamics simulations. ACS Omega. 4:19573–19581.
2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Van Aller GS, Reynoird N, Barbash O,
Huddleston M, Liu S, Zmoos AF, McDevitt P, Sinnamon R, Le B, Mas G,
et al: Smyd3 regulates cancer cell phenotypes and catalyzes histone
H4 lysine 5 methylation. Epigenetics. 7:340–343. 2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Codato R, Perichon M, Divol A, Fung E,
Sotiropoulos A, Bigot A, Weitzman JB and Medjkane S: The SMYD3
methyltransferase promotes myogenesis by activating the myogenin
regulatory network. Sci Rep. 9(17298)2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Song J, Liu Y, Chen Q, Yang J, Jiang Z,
Zhang H, Liu Z and Jin B: Expression patterns and the prognostic
value of the SMYD family members in human breast carcinoma using
integrative bioinformatics analysis. Oncol Lett. 17:3851–3861.
2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Tan X, Rotllant J, Li H, De Deyne P and Du
SJ: SmyD1, a histone methyltransferase, is required for myofibril
organization and muscle contraction in zebrafish embryos. Proc Natl
Acad Sci USA. 103:2713–2718. 2006.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Yan L, Ding B, Liu H, Zhang Y, Zeng J, Hu
J, Yao W, Yu G, An R, Chen Z, et al: Inhibition of SMYD2 suppresses
tumor progression by down-regulating microRNA-125b and attenuates
multi-drug resistance in renal cell carcinoma. Theranostics.
9:8377–8391. 2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ohtomo-Oda R, Komatsu S, Mori T, Sekine S,
Hirajima S, Yoshimoto S, Kanai Y, Otsuji E, Ikeda E and Tsuda H:
SMYD2 overexpression is associated with tumor cell proliferation
and a worse outcome in human papillomavirus-unrelated nonmultiple
head and neck carcinomas. Hum Pathol. 49:145–155. 2016.PubMed/NCBI View Article : Google Scholar
|
